CompletedPhase 2

The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial

United Kingdom111 participantsStarted 2022-07-01

Plain-language summary

The purpose of this study is to access the efficacy and safety of MC2-25 cream and MC2-25 vehicle for treatment of chronic kidney disease associated pruritus (CKD)-aP).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subjects must be established on HD or HDF 3 times per week continuously for at least 3 months prior to the start of screening and must not have plans to change from HD to HDF or vice versa during the trial
✓. Subjects who require an occasional additional HD or HDF treatment to manage fluid overload may be enrolled as long as it is anticipated that no more than 4 such treatments will be required in any given month

What they're measuring

Mean Change in Weekly Mean Worst Itch Numeric Rating Score (WI-NRS)

Timeframe: 12 weeks

Trial details

NCT IDNCT05482698

SponsorMC2 Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-02-02

Results submitted2025-01-30

View on ClinicalTrials.gov More Chronic Kidney Disease-associated Pruritus trials